FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D C | 20540 |
|--------------|------|-------|
| vasiliigion, | D.C. | 20349 |

| OMB APPROVAL | | | | | | | | | |
|---------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average b | ourden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Diamandis Peter | | | | | 2. Issuer Name and Ticker or Trading Symbol Vaxxinity, Inc. [VAXX] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | | |
|---|---|--|---|-----------|--|--|---|------|--|-------------------|---------|---|---|---|--|--|--------|--|--|--|--|
| | | | | | | | | | | | | | X | Directo | r | | 10% Ow | ner | | | |
| (Last) | (F | irst) | (Middle) | | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/20/2023 | | | | | | | | Officer below) | (give title | | Other (specification) | pecify | | |
| 505 ODYSSEY WAY | | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | |
| (Street) | | | | | | | | | | | | | | | X Form filed by One Reporting Person | | | | | | |
| MERRIT ISLAND | P1 | | 32953 | | | | | | | | | | | | Form filed by More than One Reporting Person | | | | | | |
| | | | | | - Ru | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | | |
| (City) | (S | tate) | (Zip) | | $ $ _ | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | to | | | | | | | |
| | | Tab | le I - Nor | ı-Deri | vative | Se | curities | Aco | quired, D | ispo | sed o | of, or B | enefici | ally | Owned | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date) | | | | Execution | | Date, | Transaction Dispose Code (Instr. 5) | | rities Acquired (A) o ed Of (D) (Instr. 3, 4 | | | | s ally following | Form | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | | | | |
| | | | | | | | | Code | V A | Amount (A) or (D) | | or Prio | e | | nsaction(s) str. 3 and 4) | | (| (Instr. 4) | | | |
| | | - | | | | | | | uired, Dis , options, | | | | | | wned | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | | 4. Transaction Code (Instr. 8) | | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | e and | 7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4) | | 5 | B. Price of Derivative Security Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exercisable | Expi Date | iration | Title | Amoun or Numbe of Shar | r | | Transaction(s) (Instr. 4) | | | | | |
| Stock option (right to buy) | \$2.21 | 06/20/2023 ⁽¹⁾ | | | A | | 132,352 | | (2) | | (3) | Class A common stock | 132,3 | 52 | \$0 | 132,35 | 2 | D | | | |

Explanation of Responses:

- 1. These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.
- 2. These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date
- 3. These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.

/s/ Rene Paula Molina, 06/26/2023 attorney-in-fact for Peter Diamandis

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.